Evidence map›Paper›PMID 33059424›Full record

ArticleInternational journal of health policy and management2022

Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan.

Chen-Yu Wang, Shau-Huai Fu, Chih-Chien Hung, Rong-Sen Yang, Jou-Wei Lin, Ho-Min Chen, Fei-Yuan Hsiao, Li-Jiuan Shen

Open access · diamondAbstract read
In one paragraph

Article in International journal of health policy and management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chen-Yu WangSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0003-0498-2438
Shau-Huai FuDepartment of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Douliu, Taiwan.
Chih-Chien HungDepartment of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Douliu, Taiwan.
Rong-Sen YangDepartment of Orthopedics, National Taiwan University Hospital, Taipei, Taiwan.
Jou-Wei LinCardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, Douliu, Taiwan.
Ho-Min ChenHealth Data Research Center, National Taiwan University, Taipei, Taiwan.
Fei-Yuan HsiaoSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0003-1660-9120
Li-Jiuan ShenSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-2854-3205
National Taiwan University · TWNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince 2011, Taiwan's National Health Insurance Administration (NHIA) issued a regulation on the reimbursement to anti-osteoporosis medications (AOMs). This study aimed to evaluate the impact of this regulation in reimbursement on the utilization of AOMs, clinical outcomes and associated medical expenditures of patients with incident hip fractures.

methodsBy using the National Health Insurance Research Database (NHIRD), patients with incident hip fracture from 2006 to 2015 were identified as our study cohort. Patients younger than 50 years old or prescribed with AOMs within one year prior to incident fracture were excluded. Outcomes of interest were quarterly estimates of the proportion of patients who received bone mineral density (BMD) examination, who were prescribed AOMs, as well as who encountered subsequent osteoporotic fracture-related visits and associated medical expenditures. Particularly, age- and gender specific estimates were reported. An interrupted time series study design with segmented regression model was used to quantitatively explore the impact of the changes of the reimbursement criteria on the level (immediate) and trend (long-term) changes of these outcomes.

resultsOur study enrolled 118 493 patients with incident hip fracture with those patients aged older than 80 years old accounting for the largest proportion. A significantly decreased trend of AOMs prescription rates was observed immediately post regulation except for female aged between 65 and 80, while the long-term pattern showed no significant difference. However, the percentage of patients encountered subsequent osteoporotic fracture-related visit was not statistically different between pre- and post-regulation periods. Noteworthy, the policy regulation was associated with an increasing trend of osteoporotic fracture associated medical expenditures, especially for patients older than 80 years old.

conclusionThe regulation on the reimbursement for AOMs decreased the prescribing rate of AOMs immediately although the effect did not sustain thereafter. However, higher subsequent osteoporotic fracture-related medical expenditures were introduced, especially among those very old population.

Indexed as

Hip FracturesOsteoporosisAgedAged, 80 and overBone DensityFemaleHealth ExpendituresHumansMiddle AgedTaiwanAnti-osteoporosis MedicationsNational Health InsuranceOsteoporosisOsteoporotic Fracture

Identifiers

PMID33059424
PMCPMC9309953
OpenAlexW3089894273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.